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The immune system has evolved a plethora of innate receptors that detect microbial DNA and
RNA, including Toll-like receptors in the endosomal compartment and RIG-I-like receptors and
Nod-like receptors in the cytosol. Here we discuss the recognition of and responses to non-self
nucleic acids via these receptors as well as their involvement in autoimmune diseases.
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The function of the immune system is to protect the organism
from invading pathogens. To avoid collateral damage to the
body’s own tissues, it must be able to distinguish infectious
non-self entities from self tissues. Antigen-specific lympho-
cytes - T cells and B cells - recognize pathogens through
T-cell receptors and immunoglobulins, respectively, which
are generated by somatic gene rearrangement. But although
these antigen-specific receptors allow the recognition of a
vast number of different molecules, they have no intrinsic
ability to distinguish non-self from self. Instead, it is
believed that signals delivered through the so-called pattern
recognition receptors of the innate immune system are
fundamental in recognizing infectious non-self entities, thus
preparing the body for the initiation of a full antigen-specific
immune response that targets invading pathogens but not
self tissues [1]. The receptors utilized by the innate immune
system recognize microbial components, known as pathogen-
associated molecular patterns, that are essential for the
survival of the microorganism and are therefore difficult for
it to alter. Different receptors interact with different
pathogen molecules, and show distinct expression patterns,
activate specific signaling pathways and lead to distinct anti-
pathogen responses [2,3]. The molecules recognized include,
for example, components of bacterial and fungal cell walls,
flagellar proteins and viral surface proteins - molecules that
are unique to the pathogen and not found in the host.
Another major group of pathogen molecules specifically
recognized by innate immune receptors comprises microbial
DNA and RNA. Because nucleic acids are present in all
organisms, the host has evolved specialized mechanisms for
recognizing non-self nucleic acids while maintaining
tolerance (non-responsiveness) to self nucleic acids. In this
article, we will review several systems of pattern recognition
receptors involved in the recognition of non-self nucleic
acids, including the Toll-like receptors (TLRs), the retinoic
acid-inducible gene-I (RIG-I)-like receptors (RLRs) and the
Nod-like receptors (NLRs) (Table 1). Mechanisms for
recognizing non-self nucleic acids are not fail-safe, however,
and under abnormal conditions recognition of self DNA and
RNA occurs, leading to the development of autoimmunity.
This is discussed in the last section of this review.
T TL LR Rs s   m me ed di ia at te e   r re ec co og gn ni it ti io on n   o of f   m mi ic cr ro ob bi ia al l   n nu uc cl le ei ic c   a ac ci id ds s   i in n
t th he e   e en nd do os so om ma al l   c co om mp pa ar rt tm me en nt t
Some innate immune receptors, including the TLRs and
the NLRs, recognize pathogen components via leucine-rich
repeats (LRRs) in the receptor. Of these, the TLRs are the
best studied. TLRs elicit cellular responses by signaling
through their cytoplasmic Toll-interleukin-1 receptor (TIR)
domain, which recruits TIR-containing adaptors. These
adaptors, which include MyD88, TRIF/TICAM-1, TRAM
and TIRAP/Mal, mediate intracellular events that lead to
the expression of antimicrobial and inflammatory genes
[2,4]. TLRs can be classified into two groups on the basis of
their subcellular localization. TLR1, 2, 4, 5 and 6 are all
present at the plasma membrane and recognize pathogen
components present in the extracellular milieu. The secondgroup includes TLR3, 7, 8 and 9, which localize to
intracellular compartments such as endosomes. All these
intracellular TLRs share the ability to sense viral and
bacterial nucleic acids (Figure 1), which they gain access to
when microbial DNA and RNA are released following the
degradation of endocytosed microbial particles in late
endosomes or lysosomes. As abnormal recognition of self
DNA and RNA is associated with autoimmune diseases, the
endosomal localization of nucleic acid-specific TLRs is
important in preventing their contact with self nucleic
acids [5].
TLR9 was the first TLR identified to interact with nucleic
acids, and its classical ligand is CpG DNA, an immuno-
stimulatory DNA composed of unmethylated CpG dinucleo-
tides with particular flanking sequences [6]. The CpG motif
is abundant in bacterial genomes as well as in the DNA of
viruses such as herpes simplex virus 1 (HSV-1), HSV-2 and
murine cytomegalovirus (MCMV), allowing these pathogens
to be recognized by TLR9. In contrast, in mammalian genomes
the CpG motif occurs much less frequently and is highly
methylated, which does not activate innate immunity. CpG
DNA induces a conformational change in TLR9 that is
required for its activation [7]. In addition to CpG DNA,
recent findings indicate that oligodeoxyribonucleotides con-
taining no CpG motifs but with a phosphorothioate back-
bone, or modified nucleotides with a bicyclic heterobase can
activate the innate immune system in a TLR9-dependent
manner. Therefore, TLR9 might have evolved to recognize
not only unmethylated CpG motifs as a conserved molecular
pattern in pathogen DNA but also abnormal composition,
structure or chemical features in any kind of DNA [8].
TLR9 is highly expressed in dendritic cells, the ‘professional’
antigen-presenting cells that link innate and adaptive
immune responses, and in other immune system cells such as
B cells. TLR9 expression patterns are different in humans
and mice. In mice, TLR9 is expressed broadly in the different
subsets of dendritic cells, whereas in humans it is exclusively
expressed by plasmacytoid dendritic cells (pDCs), a subtype
characterized by the ability to secrete high levels of type I
interferons in response to viral infection. In pDCs, TLR9 acts
as a sensor of viral infection, which leads to the transcription
of type I interferons, particularly interferon-α, through the
MyD88-interferon response factor 7 (IRF7) signaling
pathway. In other cells, such as conventional dendritic cells
(cDCs) and macrophages, TLR9 ligands are poor at inducing
type I interferons but they can induce inflammatory cytokines
through the MyD88-IRF1 pathway [8]. TLR9-deficient mice
show increased susceptibility to MCMV infection but not to
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Receptor family Location Ligand Receptor Adaptor
Toll-like receptors (TLRs) Endosomes CpG DNA, abnormal DNA TLR9 MyD88
ssRNA TLR7/TLR8 MyD88
dsRNA TLR3 TRIF




Nod-like receptors (NLRs) Cytosol Bacterial and viral RNA Cryopyrin ASC
F Fi ig gu ur re e   1 1
Recognition of microbial RNA and DNA by endosomal Toll-like
receptors (TLRs). TLR9, TLR7 (and TLR8), and TLR3 recognize CpG
DNA, single-stranded RNA (ssRNA), and double-stranded RNA (dsRNA),
respectively. TLR9 and TLR7/8 signal through a Toll-interleukin-1
receptor- (TIR-) containing adaptor molecule MyD88, whereas TLR3
signals exclusively through a different adaptor, TRIF. MyD88 and TRIF
induce the expression of genes for type I interferons and pro-
inflammatory cytokines by activating transcription factors of the IRF and
NFκB families. DD, death domain; IRF, interferon response factor; LRR,
leucine-rich repeat; NF, nuclear factor; SHIM, RIP homotypic interaction
motif.
















TIRlocal infection by HSV-1 [9-11], indicating a specific role for
TLR9 in viral sensing and antiviral responses.
Double-stranded RNA (dsRNA), along with its synthetic
analog polyinosinedeoxycytidylic acid (poly I:C) is a potent
inducer of the type I interferons and is recognized by TLR3
[12]. Double-stranded RNA can be generated during viral
infection as a replication intermediate for single-stranded
RNA (ssRNA) viruses or as a byproduct of symmetrical
transcription in DNA viruses. TLR3 is expressed in cDCs,
which avidly phagocytose dying cells, and in a variety of
epithelial cells, including airway, uterine and intestinal
epithelial cells that function as efficient barriers to
infection. Expression of TLR3 in these cells is also rapidly
induced by treatment with poly I:C or type I interferons.
TLR3 signals exclusively through the TLR adaptor TRIF,
leading to the IRF3-dependent induction of type I
interferons. As dsRNA is a universal viral product, TLR3
was originally thought to play a key role in antiviral
immunity. However, the induction of type I interferons and
the maturation of dendritic cells after viral infection occur
in a TLR3-independent manner [13], and TLR3-deficient
mice respond normally to infection with many viruses,
including MCMV, vesicular stomatitis virus (VSV),
lymphocytic choriomeningitis virus (LCMV) and reovirus
[14-16]. Indeed, TLR3-deficient mice are more resistant
than normal to lethal West Nile virus infection. In this
infection, a strong inflammatory response mediated by
TLR3 in peripheral tissues results in the disruption of the
blood-brain barrier, facilitating entry of the virus into the
brain, suggesting that the interaction of TLR3 with West
Nile virus actually facilitates the infection [17]. A role for
TLR3 in exacerbating immunopathology has also been
found in infection with influenza virus and Punta Toro virus
[18,19]. In vivo, therefore, TLR3 plays an important role in
evoking inflammatory responses in response to RNA virus
infection - a response that can be detrimental to the host -
rather than in the production of type I interferons. In
addition to detecting viral dsRNA, TLR3 can also be
activated by dsRNA from the helminth parasite Schistosoma
in dendritic cells [20].
The TLR7 and TLR8 genes are very similar in sequence to
each other and are both located on the X chromosome.
Mouse TLR7 and human TLR8 recognize synthetic antiviral
imidazoquinolines (such as R848 and Imiquimod), certain
guanine nucleotide analogs (for example, loxoribine), and
uridine-rich or uridine/guanosine-rich ssRNA of both viral
and host origin [21-23]. Although both TLR7 and TLR8 are
expressed in mice, mouse TLR8 appears to be
nonfunctional. TLR7 and TLR8 are present in the
endosomal membranes of pDCs, indicating that access to
ssRNA may be a key factor for activation of these cells via
these receptors. Like TLR9, TLR7 and TLR8 signal
exclusively through MyD88 to induce an interferon
response. TLR7-deficient pDCs are defective in interferon-α
production after stimulation with influenza virus [22], and
TLR7-deficient mice show increased sensitivity to VSV [23],
indicating a role for TLR7 in antiviral defense in vivo.
C Cy yt to os so ol li ic c   s se en ns so or rs s   o of f   n nu uc cl le ei ic c   a ac ci id ds s   a ar re e   u ub bi iq qu ui it to ou us s
t tr ri ig gg ge er rs s   o of f   i in nt te er rf fe er ro on n   r re es sp po on ns se es s
In 1963, two groups, including one led by the discoverer of
interferon, Alick Isaacs, reported that DNA and RNA derived
from pathogens or host cells were able to activate chicken or
mouse fibroblasts to produce interferon [24,25]. TLRs specific
for nucleic acids are expressed only in a subset of immune-
system cells, whereas almost all nucleated cells can produce
type I interferons in response to viral infection, and so TLRs
are unlikely to mediate the interferon response in fibroblasts.
Indeed, fibroblasts lacking the key TLR adaptors MyD88 and
TRIF are still capable of inducing type I interferons after viral
infection, indicating that TLRs are not required for viral
detection in these cells [26]. Recent studies indicate that the
ubiquitous interferon response to immunostimulatory nucleic
acids is mediated by cytosolic RNA-binding proteins - the RLR
family and by cytosolic DNA sensors that include the recently
identified protein DAI (DNA-dependent activator of
interferon-regulatory factors) (Figure 2).
RIG-I and melanoma differentiation-associated gene 5
(MDA5)/Helicard are DExD/H box RNA helicases that have
recently been implicated in the regulation of interferon gene
expression following sensing of viral RNA in the cytosol.
Both of these proteins contain caspase recruitment and
activation domains (CARDs) and detect RNA viruses and
synthetic poly I:C [27-29]. The critical determinant in RIG-I
stimulation by RNA is the presence of triphosphates at the 5’
end of ssRNA [30,31]. Host 5’-triphosphate ssRNA exist in
the nucleus but not the cytoplasm; host ssRNA in the
cytoplasm are normally capped or processed. The agonist for
MDA5 remains uncharacterized, although MDA5 is known
to respond to dsRNA. A third member of the RLR family, the
protein LGP2, shares homology with RIG-I and MDA5 in the
helicase domain and can bind dsRNA. However, LGP2 lacks
a CARD domain and has been proposed to act as a negative
regulator of RIG-I or MDA5 signaling [32,33].
Upon RNA recognition, RIG-I and MDA5 signal through the
adaptor molecule interferon-β promoter stimulator 1 (IPS-1,
also known as MAVS, Cardif and VISA) to downstream
signaling proteins that include the adaptor Fas-associated
death domain-containing protein (FADD), and the death-
domain-containing kinase RIP1, TANK-binding kinase 1
(TBK1) and the inducible I-kappaB kinase (IKK-i), leading to
transcription of the interferon genes [2,34]. Experiments
with mice deficient in RIG-I or MDA5 indicate that the two
helicases are critical for host antiviral responses and
distinguish different viruses [35,36]. RIG-I is essential for
the production of interferon in response to RNA viruses such
as paramyxoviruses, influenza virus and Japanese encephalitis
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Furthermore, compared with control mice, RIG-I-/- and
MDA5 -/- mice are highly susceptible to infection with the
respective RNA viruses [35,36].
A pathway analogous to that stimulated by RIG-I and MDA5
has been suggested to signal an innate immune response to
DNA in the cytosol. HSV-1 elicits type I interferon produc-
tion via both TLR9-independent and -dependent pathways
[37]. Similarly, cytosolic DNA has been shown to be an
interferon-activating ligand independent of TLRs in
intracellular infection with the bacterium Listeria mono-
cytogenes [38]. Cytosolic DNA sensing does not require
RIG-I or MDA5 [39], suggesting the involvement of a new
factor. The first cytosolic DNA sensor identified was the
interferon-inducible protein DAI, which can activate IRF3
and induce an interferon response in cells [40]. Binding of
dsDNA to DAI enhances the protein’s association with the
transcription factor IRF3 and the kinase TBK1. Over-
expression of DAI in mouse fibroblasts selectively enhances
DNA-mediated induction of type I interferons and of other
genes involved in innate immunity. Thus, DAI may be
central to detection of the DNA of viruses, bacteria, fungi
and parasites that enter host cells. Generation and analysis
of mice deficient in DAI should define its function more
clearly. Inhibition of DAI synthesis by small interfering
RNAs reduced interferon production after DNA stimulation
but did not abolish it [40], suggesting that additional
cytosolic DNA sensors might exist.
T Th he e   i in nd du uc ct ti io on n   o of f   n no on n- -t tr ra an ns sc cr ri ip pt ti io on na al l   r re es sp po on ns se es s   t to o
n nu uc cl le ei ic c   a ac ci id ds s
A common feature of the recognition of non-self nucleic
acids by TLRs, RLRs and DAI is their ability to induce robust
activation of genes for interferons and/or pro-inflammatory
cytokines, which endow these receptors with a central role in
innate immunity. Various other mechanisms that recognize
non-self nucleic acids do not result in gene activation. One
important post-transcriptional pathway for the regulation of
innate immunity is mediated by the intracellular NLRs
[41,42]. These cytosolic pattern recognition receptors induce
the activation of the protease caspase-1 through the
assembly of large protein complexes called inflammasomes.
One of the NLRs, cryopyrin/Nalp3, mediates caspase-1
activation and the processing and secretion of the cytokines
interleukin 1β (IL-1β) and IL-18 in response to bacterial and
viral RNA, poly I:C and the imidazoquinolines R837 and
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Recognition of microbial RNA and DNA by cytoplasmic pattern recognition receptors. RIG-I and MDA5 recognize 5’-triphosphate ssRNA and dsRNA
from RNA viruses and trigger signaling cascades via a CARD-containing adaptor molecule, IPS-1. IPS-1 induces the expression of genes for type I
interferons and pro-inflammatory cytokines by activating transcription factors of the IRF and NFκB families. The role of LGP2 in RNA virus recognition is
unclear and LGP2 has been proposed to inhibit RIG-I activity. DAI recognizes dsDNA and induces gene expression through an unknown adaptor
molecule. Modular structures of the receptor proteins are shown with the abbreviations of the domains as follows: CARD, caspase activating
recruitment domains; helicase, RNA-binding domain; RD, repressor domain; TM, transmembrane domain; Zα and Zβ, Z-DNA binding domain α and β;


















Helicase RD Helicase Zα Zβ D3 SD RIG-1
TMR848 as well as to viral infection [43]. Whether
cryopyrin/Nalp3 directly recognizes RNA and imidazo-
quinoline is unclear, because no direct association has been
reported. NLRX1, a mitochondrially localized NLR, plays a
negative role in antiviral immunity by antagonizing the
interaction between RIG-I and IPS-1, suggesting that NLRX1
functions as a modulator of the responses to pathogen
components rather than as a receptor that regulates antiviral
innate immunity [44].
Several enzymes whose activities depend on the presence of
dsRNA are also involved in innate immunity. One
mechanism involves two enzymes, protein kinase R (PKR)
and general control nonderepressible-2 (GCN-2), which
phosphorylate the α subunit of translation initiation factor
2, leading to the downregulation of protein translation, and
therefore of virus replication, within infected cells [45]. In
PKR-deficient mice, antiviral responses are reduced when
dsRNA or interferon are given along with the virus as
coactivators. However, PKR deficiency does not affect the
induction of type I interferons by dsRNA and viruses,
suggesting that PKR is acting as an effector of interferon
action rather than in the induction of interferon synthesis.
Another protein that is stimulated by dsRNA is 2’-5’ oligo-
adenylate synthetase, an enzyme that synthesizes short
oligoadenylates that in turn activate the endoribonuclease
RNase L. Upon activation, RNase L promotes the cleavage of
both cellular and viral RNAs. As with PKR, the analysis of
RNase L-deficient mice revealed the requirement for this
enzyme in interferon-dependent antiviral actions [46].
Although PKR and RNase L become activated by dsRNA and
are implicated in antiviral immunity, they are mainly
effectors of interferon action and are dispensable for
interferon production, and generally are not defined as
pattern recognition receptors.
S Se en ns si in ng g   o of f   s se el lf f   n nu uc cl le ei ic c   a ac ci id ds s   c ca an n   r re es su ul lt t   i in n   a au ut to oi im mm mu un ni it ty y
Although all the defense mechanisms described above are
designed for the recognition of microbial nucleic acids, they
can in some circumstances lead to the recognition of host
DNA and RNA and the development of autoimmunity [47].
TLRs specific for nucleic acids are normally localized to the
endosomal compartment, which may be the safeguard
against contact with self DNA [5]. Unfortunately for the
host, endogenous RNA and DNA are also able to activate
TLR7 and TLR9 if they enter the endosomal compartment. A
rich potential source of self RNA and DNA are the remains of
host cells that have died via necrosis or apoptosis. Normally
such apoptotic debris appears to be cleared rapidly by
macrophages, which in humans do not express TLR7 or
TLR9. But if there is a delay in apoptotic clearance, or if
there are autoantibodies that interact with the antigens
exposed on the apoptotic cells, this material can be mis-
directed to pDCs and B cells, where the nucleic acids can
activate TLR7 and/or TLR9, resulting in the secretion of type
I interferons by pDCs and the differentiation of B cells into
plasma cells. Such a mechanism is likely to be the cause of
pDC secretion of type I interferons in systemic lupus
erythematosus (SLE) patients, in which increased serum
concentrations of interferon-α correlate with disease activity
and probably contribute to disease pathogenesis. In the
mouse model of SLE, the genetic locus Y chromosome-
linked autoimmune accelerator (Yaa) acts as a disease
accelerator, promoting SLE in genetically susceptible
mouse strains. Recent genetic studies revealed that Yaa is
a duplication and translocation of the TLR7 gene from the
X chromosome onto the Y chromosome, increasing the
dosage of the TLR7 gene in the cell [48,49]. Further studies
showed that the gene dosage of TLR7 is directly related to
the risk of autoimmunity [50].
TLR-independent mechanisms for the recognition of self
nucleic acids also contribute to autoimmunity. Deoxyribo-
nuclease II (DNase II) in macrophages cleaves the DNA of
engulfed apoptotic cells and of engulfed nuclei that have
been expelled from erythroid precursor cells. In mice
deficient in DNase II, genomic DNA cannot be degraded and
accumulates in the macrophage phagosome, leading to TLR-
independent, interferon-mediated autoimmune pathology
[51]. Whether DAI or other cytosolic DNA sensors contribute
to such autoimmunity awaits further investigation.
The discovery of pattern recognition receptors has thus
revolutionized  our understanding of innate immunity,
explaining why and how multiple and diverse infectious
agents are recognized by a limited number of innate
immune receptors that trigger antimicrobial responses [1].
We are beginning to appreciate how a variety of such
receptors at distinct cellular localizations recognize non-self
nucleic acids derived from infectious microorganisms and
initiate a proper immune response against them, while at
the same time maintaining tolerance to self DNA and RNA
to prevent development of autoimmunity. How such a
delicate balance is established is not well understood and it
probably involves both the receptors themselves and the
way host nucleic acids are handled in the cell. For example,
sequestration of certain TLRs in the endosomal
compartments and packaging of mammalian DNA into
high-order chromatin structure may both prevent the
accidental activation of innate responses to self nucleic
acids. It will also be important to dissect the molecular
mechanisms and structural basis of the interactions of these
receptors with their ligands, a task that should become
easier following the recent elucidation of the structures of
several TLRs [52-55]. Finally, the mechanisms underlying
the sensing of cytosolic DNA by DAI and other possible
factors have not yet been established and await further
investigation. Eventually, research on innate recognition of
non-self nucleic acids is likely to be translated into the
development of new strategies for the prevention and
therapy of infectious and autoimmune diseases.
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